BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16157365)

  • 21. The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer.
    Edwards J; Traynor P; Munro AF; Pirret CF; Dunne B; Bartlett JM
    Clin Cancer Res; 2006 Jan; 12(1):123-30. PubMed ID: 16397033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
    Yonemori K; Tsuta K; Shimizu C; Hatanaka Y; Hirakawa A; Ono M; Kouno T; Katsumata N; Ando M; Tamura K; Hasegawa T; Kinoshita T; Fujiwara Y
    J Surg Oncol; 2010 Mar; 101(3):222-7. PubMed ID: 20087905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.
    Ang KK; Berkey BA; Tu X; Zhang HZ; Katz R; Hammond EH; Fu KK; Milas L
    Cancer Res; 2002 Dec; 62(24):7350-6. PubMed ID: 12499279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pretreatment proliferation parameters do not add predictive power to clinical factors in cervical cancer treated with definitive radiation therapy.
    Tsang RW; Juvet S; Pintilie M; Hill RP; Wong CS; Milosevic M; Chapman W; Levin W; Manchul LA; Fykes AW
    Clin Cancer Res; 2003 Oct; 9(12):4387-95. PubMed ID: 14555510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential cyclooxygenase-2 expression in squamous cell carcinoma and adenocarcinoma of the uterine cervix.
    Kim YB; Kim GE; Pyo HR; Cho NH; Keum KC; Lee CG; Seong J; Suh CO; Park TK
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):822-9. PubMed ID: 15465199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of Bax, Bcl-2, and p53 expressions in cervical squamous cell carcinoma treated by radiotherapy.
    Wootipoom V; Lekhyananda N; Phungrassami T; Boonyaphiphat P; Thongsuksai P
    Gynecol Oncol; 2004 Sep; 94(3):636-42. PubMed ID: 15350352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer.
    Matsubara J; Yamada Y; Hirashima Y; Takahari D; Okita NT; Kato K; Hamaguchi T; Shirao K; Shimada Y; Shimoda T
    Clin Cancer Res; 2008 May; 14(10):3022-9. PubMed ID: 18483367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: Implications for targeted radionuclide therapy.
    Wei Q; Shui Y; Zheng S; Wester K; Nordgren H; Nygren P; Glimelius B; Carlsson J
    Oncol Rep; 2011 Jan; 25(1):3-11. PubMed ID: 21109951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Negative prognostic impact of the coexpression of epidermal growth factor receptor and c-erbB-2 in locally advanced cervical cancer.
    Pérez-Regadera J; Sánchez-Muñoz A; De-la-Cruz J; Ballestín C; Lora D; García-Martín R; Mendiola C; Alonso L; Alba E; Lanzós E
    Oncology; 2009; 76(2):133-41. PubMed ID: 19174612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
    Wang KL; Wu TT; Choi IS; Wang H; Resetkova E; Correa AM; Hofstetter WL; Swisher SG; Ajani JA; Rashid A; Albarracin CT
    Cancer; 2007 Feb; 109(4):658-67. PubMed ID: 17211865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.
    Witton CJ; Reeves JR; Going JJ; Cooke TG; Bartlett JM
    J Pathol; 2003 Jul; 200(3):290-7. PubMed ID: 12845624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct characteristics of heregulin signals mediated by HER3 or HER4.
    Weiss FU; Wallasch C; Campiglio M; Issing W; Ullrich A
    J Cell Physiol; 1997 Nov; 173(2):187-95. PubMed ID: 9365520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study.
    Kristensen GB; Holm R; Abeler VM; Tropé CG
    Cancer; 1996 Aug; 78(3):433-40. PubMed ID: 8697388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
    Chakravarti A; Winter K; Wu CL; Kaufman D; Hammond E; Parliament M; Tester W; Hagan M; Grignon D; Heney N; Pollack A; Sandler H; Shipley W
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):309-17. PubMed ID: 15890569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nuclear Y-box-binding protein-1 is a poor prognostic marker and related to epidermal growth factor receptor in uterine cervical cancer.
    Nishio S; Ushijima K; Yamaguchi T; Sasajima Y; Tsuda H; Kasamatsu T; Kage M; Ono M; Kuwano M; Kamura T
    Gynecol Oncol; 2014 Mar; 132(3):703-8. PubMed ID: 24486603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential ErbB receptor expression and intracellular signaling activity in lung adenocarcinomas and squamous cell carcinomas.
    López-Malpartida AV; Ludeña MD; Varela G; García Pichel J
    Lung Cancer; 2009 Jul; 65(1):25-33. PubMed ID: 19046792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
    Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
    J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ErbB-3 predicts survival in ovarian cancer.
    Tanner B; Hasenclever D; Stern K; Schormann W; Bezler M; Hermes M; Brulport M; Bauer A; Schiffer IB; Gebhard S; Schmidt M; Steiner E; Sehouli J; Edelmann J; Läuter J; Lessig R; Krishnamurthi K; Ullrich A; Hengstler JG
    J Clin Oncol; 2006 Sep; 24(26):4317-23. PubMed ID: 16896008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Correlation of serum squamous cell carcinoma antigen with clinico-pathological features and prognosis of squamous cell carcinoma of uterine cervix].
    Xiong Y; Liang LZ; Zheng M; Wei M; Shen Y
    Zhonghua Fu Chan Ke Za Zhi; 2007 Jan; 42(1):29-33. PubMed ID: 17331418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Immunohistochemical study of the predictive value of oncoproteins p53, HER-2 and c-myc during radiotherapy for squamous cell carcinoma of the cervix].
    Gasparian NA; Pozharisskiĭ KM; Zharinov GM; Vinokurov VL; Kuznetsova ME; Neklasova NIu
    Vopr Onkol; 2007; 53(4):439-44. PubMed ID: 17969407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.